收起

掌上阜外
官方微信
官方微博
我要挂号
意见信箱
我要求职
我要进修
志愿服务
返回顶部
  • 人才队伍
  • PI介绍

王淼教授

发布时间:2019-11-21 15:38:53

王淼,药理学研究员

国家高层次人才计划获得者,科技部中青年科技创新领军人才,“药明康德”生命化学研究奖学者奖。美国心脏协会(AHA)资深会员(FAHA),美国心脏协会(AHA)科学年组委会委员、美中医药开发协会(SAPA)终身会员(2009-2010 SAPA-GP常务理事),中国微循环学会理事,中国老年学和老年医学学会老年病学分会常务委员,中国生理学会血栓与止血专业委员会委员,中国病理生理学会受体与信号转导委员会委员。

2002年毕业于北京协和医学院,获得免疫学方向博士学位。在美国宾西法尼亚大学(University of Pennsylvania)药理系做博士后,并获得临床研究认证(临床流行病学与生物统计学),2006年起先后担任药理学研究教职至研究助理教授。 2010起任美国辉瑞制药公司全球研发中心的项目首席科学家(Principal Scientist)。2013年就职于阜外医院,药理学研究员,阜外医院学术委员会委员(2016至今)、伦理委员会委员(2019至今)。Redox BiologyBiochemical Pharmacology期刊编委。

办公电话:010—60266377


课题组简介

主要研究方向是心血管疾病、微循环与血栓调节机制与新药发现。发表代表性通讯作者论文于Nat Commun、Circulation、 Circ Res、Arterioscler Thromb Vasc BiolBr J Pharmacol等学术期刊。主编《Coronary Artery Disease: Therapeutics and Drug Discovery / 冠心病:治疗与药物发现》英文书, Springer出版社;共同主编《抗血栓治疗-新药与治疗策略》科学出版社。


Miao Wang PhD, FAHA

Professor of Pharmacology

State Key Laboratory of Cardiovascular Disease

Fuwai Hospital

National Center for Cardiovascular Diseases

Peking Union Medical College and Chinese Academy of Medical Sciences

miao.wang@pumc.edu.cn

Dr. Wang obtained a Ph.D. degree in biophysics/immunology from Chinese Academy of Medical Sciences in 2002. He completed postdoctoral research and obtained a Clinical Research Certificate in Clinical Epidemiology & Biostatistics at University of Pennsylvania, and then joined the Department of Pharmacology as Research Associate and Research Assistant Professor from 2006-2010.

Dr. Wang joined Pfizer Inc as Principal Scientist in 2010 and had been leading several cardiovascular drug discovery programs until he took the current position in 2013.

Dr. Wang is a fellow of American Heart Association (FAHA) and serves in the program committees for the American Heart Association (AHA) Scientific Sessions. He serves in the early career committee of the Arteriosclerosis, Thrombosis and Vascular Biology Council of AHA (2012-2021). He is an editorial board member for “Redox Biology” and “Biochemical Pharmacology”.

Dr. Wang’s research aims to elucidate the mechanisms of coronary artery disease, with a particular focus on inflammation and thrombosis, and to translate novel mechanistic insights into therapeutic innovation. He discovers that the increased risk of thrombosis associated with cyclooxygenase-2 selective NSAIDs is attributable to suppression of COX-2 derived prostacyclin, and that inhibition of mPGES-1, a therapeutic target downstream of COX-2 pathway, can bypass the thrombotic risk and has therapeutic relevance for vascular restenosis and myocardial infarction. He uncovers that prostaglanding E2, through acting on its receptor EP4 on the endothelium, promotes microvascular salvage in myocardial ischemia/reperfusion, protecting against myocardial injury. He recently identified phorsphodiesterase-4B as a novel therapeutic target for acute myocardial infarction, which provides cardioprotection by both anti-inflammation and microcirculation preservation. He is chief editor of the book “Coronary Artery Disease: Therapeutics and Drug Discovery” (Springer Press).

Representative publications:

1) Zhang Y, Steinmetz-Späh J, Idborg H, Zhu L, Li H, Rao H, Chen Z, Guo Z, Hu L, Xu C, Chen H, Korotkova M, Jakobsson PJ*, Wang M* (*Corresponding author). Microsomal prostaglandin E synthase-1 inhibition prevents adverse cardiac remodeling after myocardial infarction in mice. Br J Pharmacol. 2023 Aug;180(15):1981-1998.

2) Wan Q, Xu C, Zhu L, Zhang Y, Peng Z, Chen H, Rao H, Zhang E, Wang H, Chu F, Ning X, Yang X, Yuan J, Wu Y, Huang Y, Hu S, Liu DP, Wang M*. Targeting PDE4B (Phosphodiesterase-4 Subtype B) for Cardioprotection in Acute Myocardial Infarction via Neutrophils and Microcirculation. Circ Res. 2022;131(5):442-55.

3) Zhu L, Xu C, Huo X, Hao H, Wan Q, Chen H, Zhang X, Breyer RM, Huang Y, Cao X, Liu DP, FitzGerald GA, Wang M* . The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury. Nat Commun. 2019;10(1):1888.

4) Hao H, Hu S, Wan Q, Xu C, Chen H, Zhu L, Xu Z, Meng J, Breyer RM, Li N, Liu DP, FitzGerald GA, Wang M*. Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury. Arterioscler Thromb Vasc Biol. 2018;38(5):1115-1124.

5) Hao H, Hu S, Chen H, Bu D, Zhu L, Xu C, Chu F, Huo X, Tang Y, Sun X, Ding B, Liu D, Hu S, Wang M*. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis, and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017; 135(13):1253-1264.



研究团队合照


上一篇: 王淼教授